# Acadia Realty Trust: financial statements, quarterly

AKR · NYSE · CIK 899629 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akr.md) · [Financials](/companies/akr/financials.md) · [Filings](/companies/akr/filings.md) · [Insiders](/companies/akr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/akr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [81.4](/filings/0000950170-24-117714.md) | [85.5 d](/filings/0001193125-26-051677.md) | [91.4](/filings/0000950170-24-050536.md) | [87.3](/filings/0000950170-24-088594.md) | [87.7](/filings/0000950170-24-117714.md) | [93.3 d](/filings/0001193125-26-051677.md) | [104](/filings/0001193125-26-191611.md) | [101](/filings/0001193125-26-323776.md) | not reported | not reported | [103](/filings/0001193125-26-191611.md) | [95.4](/filings/0001193125-26-323776.md) |
| Operating income | $m | [6.7](/filings/0000950170-24-117714.md) | [10.6 d](/filings/0001193125-26-051677.md) | [14.0](/filings/0000950170-25-061198.md) | [17.8](/filings/0000950170-25-100264.md) | [17.5](/filings/0001193125-25-256341.md) | [16.4 d](/filings/0001193125-26-051677.md) | [15.3](/filings/0001193125-26-191611.md) | [0.8](/filings/0001193125-26-323776.md) | [12.7](/filings/0001193125-25-256341.md) | [20.7 d](/filings/0001193125-26-051677.md) | [159](/filings/0001193125-26-191611.md) | [22.7](/filings/0001193125-26-323776.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-24-117714.md) | [0.1 d](/filings/0001193125-26-051677.md) | [0.0](/filings/0000950170-25-061198.md) | [0.2](/filings/0000950170-25-100264.md) | [0.0](/filings/0001193125-25-256341.md) | [0.0 d](/filings/0001193125-26-051677.md) | [0.1](/filings/0001193125-26-191611.md) | [0.2](/filings/0001193125-26-323776.md) | [0.0](/filings/0001193125-25-256341.md) | [0.1 d](/filings/0001193125-26-051677.md) | [0.0](/filings/0001193125-26-191611.md) | [0.2](/filings/0001193125-26-323776.md) |
| Net income | $m | [(16.3)](/filings/0000950170-24-117714.md) | [11.4 d](/filings/0001193125-26-051677.md) | [(6.9)](/filings/0000950170-25-061198.md) | [1.6](/filings/0000950170-25-100264.md) | [12.3](/filings/0001193125-25-256341.md) | [14.7 d](/filings/0001193125-26-051677.md) | [(11.7)](/filings/0001193125-26-191611.md) | [(20.9)](/filings/0001193125-26-323776.md) | [(11.0)](/filings/0001193125-25-256341.md) | [60.5 d](/filings/0001193125-26-051677.md) | [139](/filings/0001193125-26-191611.md) | [22.8](/filings/0001193125-26-323776.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0000950170-24-117714.md) | not reported | [0.03](/filings/0000950170-25-061198.md) | [0.01](/filings/0000950170-25-100264.md) | [0.07](/filings/0001193125-25-256341.md) | not reported | [0.01](/filings/0001193125-26-191611.md) | [0.01](/filings/0001193125-26-323776.md) | [0.03](/filings/0001193125-25-256341.md) | not reported | [0.22](/filings/0001193125-26-191611.md) | [0.05](/filings/0001193125-26-323776.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0000950170-24-117714.md) | not reported | [0.03](/filings/0000950170-25-061198.md) | [0.01](/filings/0000950170-25-100264.md) | [0.07](/filings/0001193125-25-256341.md) | not reported | [0.01](/filings/0001193125-26-191611.md) | [0.01](/filings/0001193125-26-323776.md) | [0.03](/filings/0001193125-25-256341.md) | not reported | [0.22](/filings/0001193125-26-191611.md) | [0.05](/filings/0001193125-26-323776.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.3](/filings/0000950170-24-117714.md) | [17.5](/filings/0001193125-26-051677.md) | [18.8](/filings/0000950170-25-061198.md) | [31.9](/filings/0000950170-25-100264.md) | [46.2](/filings/0001193125-25-256341.md) | [16.8](/filings/0001193125-26-323776.md) | [32.0](/filings/0001193125-26-191611.md) | [42.8](/filings/0001193125-26-323776.md) | [49.4](/filings/0001193125-25-256341.md) | [38.8](/filings/0001193125-26-323776.md) | [31.4](/filings/0001193125-26-191611.md) | [33.0](/filings/0001193125-26-323776.md) |
| Total assets | $m | [4,281](/filings/0000950170-24-117714.md) | [4,291](/filings/0001193125-26-051677.md) | [4,272](/filings/0000950170-25-061198.md) | [4,251](/filings/0000950170-25-100264.md) | [4,276](/filings/0001193125-25-256341.md) | [4,371](/filings/0001193125-26-051677.md) | [4,736](/filings/0001193125-26-191611.md) | [4,876](/filings/0001193125-26-323776.md) | [4,875](/filings/0001193125-25-256341.md) | [4,837](/filings/0001193125-26-323776.md) | [4,533](/filings/0001193125-26-191611.md) | [4,618](/filings/0001193125-26-323776.md) |
| Total liabilities | $m | [2,101](/filings/0000950170-23-056974.md) | [2,158](/filings/0000950170-25-021145.md) | [2,000](/filings/0000950170-24-050536.md) | [1,971](/filings/0000950170-24-088594.md) | [1,866](/filings/0000950170-24-117714.md) | [1,839](/filings/0001193125-26-051677.md) | [1,947](/filings/0000950170-25-061198.md) | [2,148](/filings/0000950170-25-100264.md) | [2,210](/filings/0001193125-25-256341.md) | [2,208](/filings/0001193125-26-323776.md) | [1,889](/filings/0001193125-26-191611.md) | [1,937](/filings/0001193125-26-323776.md) |
| Long-term debt | $m | [1,820](/filings/0000950170-23-056974.md) | [1,870](/filings/0000950170-25-021145.md) | [1,724](/filings/0000950170-24-050536.md) | [1,696](/filings/0000950170-24-088594.md) | [1,580](/filings/0000950170-24-117714.md) | [1,537](/filings/0001193125-26-051677.md) | [1,626](/filings/0000950170-25-061198.md) | [1,804](/filings/0000950170-25-100264.md) | [1,862](/filings/0001193125-25-256341.md) | [1,863](/filings/0001193125-26-323776.md) | [1,596](/filings/0001193125-26-191611.md) | [1,637](/filings/0001193125-26-323776.md) |
| Shareholders' equity | $m | [1,685](/filings/0000950170-23-056974.md) | [1,637](/filings/0000950170-25-021145.md) | [1,761](/filings/0000950170-24-050536.md) | [1,781](/filings/0000950170-24-088594.md) | [1,927](/filings/0000950170-24-117714.md) | [2,066](/filings/0001193125-26-051677.md) | [2,298](/filings/0000950170-25-061198.md) | [2,269](/filings/0000950170-25-100264.md) | [2,246](/filings/0001193125-25-256341.md) | [2,226](/filings/0001193125-26-323776.md) | [2,277](/filings/0001193125-26-191611.md) | [2,337](/filings/0001193125-26-323776.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [25.7 d](/filings/0000950170-24-117714.md) | [40.6 d](/filings/0001193125-26-051677.md) | [26.0](/filings/0000950170-25-061198.md) | [32.0 d](/filings/0000950170-25-100264.md) | [44.6 d](/filings/0001193125-25-256341.md) | [37.9 d](/filings/0001193125-26-051677.md) | [25.9](/filings/0001193125-26-191611.md) | [64.8 d](/filings/0001193125-26-323776.md) | [34.3 d](/filings/0001193125-25-256341.md) | [42.0 d](/filings/0001193125-26-051677.md) | [31.4](/filings/0001193125-26-191611.md) | [58.3 d](/filings/0001193125-26-323776.md) |
| Dividends paid | $m | [17.2 d](/filings/0000950170-24-117714.md) | [17.2 d](/filings/0001193125-26-051677.md) | [17.2](/filings/0000950170-25-061198.md) | [18.6 d](/filings/0000950170-25-100264.md) | [18.9 d](/filings/0001193125-25-256341.md) | [21.6 d](/filings/0001193125-26-051677.md) | [22.7](/filings/0001193125-26-191611.md) | [26.2 d](/filings/0001193125-26-323776.md) | [26.2 d](/filings/0001193125-25-256341.md) | [26.2 d](/filings/0001193125-26-051677.md) | [26.2](/filings/0001193125-26-191611.md) | [26.7 d](/filings/0001193125-26-323776.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [95.3](/filings/0000950170-23-056974.md) | [95.2](/filings/0000950170-24-050536.md) | [95.3](/filings/0000950170-24-088594.md) | [95.3](/filings/0000950170-24-117714.md) | [102](/filings/0000950170-25-061198.md) | [104](/filings/0000950170-25-100264.md) | [108](/filings/0001193125-25-256341.md) | [121](/filings/0001193125-26-191611.md) | [131](/filings/0001193125-26-323776.md) | [131](/filings/0001193125-25-256341.md) | [131](/filings/0001193125-26-191611.md) | [134](/filings/0001193125-26-323776.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 137,332,722 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-323776.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.